CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.13 USD
-0.06 (-5.04%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.15 +0.02 (1.77%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.13 USD
-0.06 (-5.04%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.15 +0.02 (1.77%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Zacks News
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CARISMA THERAP (CARM) delivered earnings and revenue surprises of 25% and 151.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.